31 results about "Rifapentine" patented technology

The present invention relates to a method for treating, ameliorating, reversing and / or preventing autism or an autism spectrum disorder (ASD) via the administration of a formulation, a pharmaceuticalpreparation or a pharmaceutical composition comprising or consisting of: (a) a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIXT), an extended intestinal release (EIR) rifaximin, a rifamycin derivative, a rifampicin (or rifampin) (optionally RIFADIN), a rifabutin (optionally MYCOBUTIN), a rifapentine (optionally PRIFTIN), a rifalazil, a bicozamycin, or a mixture or combination thereof, or (b)a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIX) and at least one additional antimicrobial or antibiotic agent, wherein optionally the at least one additional antimicrobial or antibiotic agentcomprises a vancomycin, a metronidazole (optionally FLAGYLTM, METROTM), a tinidazole (optionally FASIGYN, SIMPLOTAN, TINDAMAX) or a combination thereof

The invention discloses an agent for yellow shoot prevention and control. The agent is applied by a trunk transfusion method. Each 100mL of the agent mainly comprises 0.5-1 gram of penbritin, 0.2-0.5 gram of rifapentine, 0.5-2mL of 1,2-butanediol serving as a stabilizer, 0.1-2mL of glycol serving as an anti-freezing agent, 0.1-2mL of azone serving as a novel permeation promoter, 0.1-2 grams of sodium lignin sulfonate serving as a dispersing agent, 0.1-2 grams of sodium dodecyl benzene sulfonate serving as an emulsifier, 0.1-2mL of DMSO (dimethyl sulfoxide) serving as a co-solvent and the rest deionized water supplemented to reach 100mL. Different bactericides are reasonably mixed by two sterilization mechanisms according to the objective requirement of yellow shoot prevention and control, the agent can achieve complementary advantages and has the advantages of high efficiency, low toxicity, safety, economization and multifunction, and yellow shoot can be more effectively prevented and controlled.

The invention belongs to the field of rifamycin adsorption materials, and in particular relates to a polyphenol-modified gamma-type alumina-based porous carbon composite material, a preparation method and an application. The polyphenol-modified gamma-type alumina-based porous carbon composite material is gamma-(Al 2 o 3 ) 1.333 / C BT‑900 Composite materials are composed of nanoparticles with a length of 100-200 nm and uniform size. Polyphenol-modified gamma-type alumina-based porous carbon composite material gamma-Al provided by the invention 2 o 3 / C BT‑900 As a new removal material for rifapentine molecules, it can exert the synergistic effect of nanoporous carbon and metal oxides, further increase the specific surface area of ​​the material, and increase the contact area and adsorption sites with rifapentine. Using it as a novel adsorbent for rifapentine shows good adsorption performance.

The invention, relating to both the technical field of biology and medicine, discloses rifapentine sustained-released microspheres and a preparation method thereof. The rifapentine sustained-released microspheres disclosed herein have high drug loading capacity, good entrapment efficiency, and good sustained action by in vitro release test. The rifapentine sustained-released microspheres disclosed herein can be directly implanted into tuberculosis local focus to conduct regional continuous chemotherapy to let the tuberculosis focus position have large drug amount, high drug concentration, long duration, large effect, good local curative effect, little amount of the drug distributed to the whole body, and low plasma concentration, thus the curative effect is raised, and the effect of adverse reaction is significantly reduced, so that good treatment of patients (severe liver and kidney dysfunction, combination of a plurality of systemic diseases, severe malnutrition) who can not endure anti-tuberculosis chemotherapy can be achieved. The preparation method of the rifapentine sustained-released microspheres has the advantages of low cost, simple operation, and convenient, simple and repeatable method, and can generate huge economic benefits.

The slow released antituberculotic preparation is implanting agent or injection with slow releasing of medicine in the local tuberculosis focus to maintain the local effective medicine concentration while lowing the systemic toxicity. The slow released injection consists of slow released microsphere and solvent. The slow released microsphere consists of slow releasing supplementary material and antituberculotic selected from rifampicin, rifamycin, rifapentine and / or rifabutine. The solvent is special solvent containing suspending agent of carboxymethyl cellulose sodium, etc. and has viscosityof 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released preparation may be prepared with slow released microsphere. The present invention has obvious and unique treating effect on various kinds of intractable tuberculosis.

The present invention relates to an oral pharmaceutical fixed dose composition in a form of a dispersible tablet for use in the treatment of tuberculosis, said oral pharmaceutical composition comprising: a) granules comprising isoniazid and at least one intragranular excipient, b) granules comprising rifapentine and at least one intragranular excipient, and c) at least one extragranular excipient, and to its process of preparation.

The present invention features an antibacterial composition comprising 1) a composition A comprising polymyxin B and trimethoprim; and 2) an antibiotic agent selected from the group consisting of rifampicin, rifabutin, rifapentine, rifaximin, pefloxacin mesylate, sparfloxacin, sarafloxacin HCl, tobramycin, lomefloxacin, besifloxacin, danofloxacin mesylate, enrofloxacin, nadifloxacin and clinafloxacin, a topical pharmaceutical thereof, and a method of treating bacterial infections using mixtures of 1 and 2.

The invention discloses a rifapentine capsule and a preparation method thereof. Tween 80, HPMC and K 12 Add pure ethanol to dissolve into a binder, use the binder to spray rifapentine to obtain rifapentine granules; then add HPMC, BHA and vitamin C to dissolve into pure ethanol to form a coating solution, and use The coating solution sprays and coats the rifapentine granules to obtain rifapentine coated granules; finally mixes the rifapentine coated granules with pregelatinized starch for total mixing and then fills , to prepare rifapentine capsules. Adopting the method of the present invention to prepare rifapentine capsules solves the problem of fluidity of the intermediate powder of the original preparation of rifapentine capsules, so as to solve the problems of related substances exceeding the standard and large differences in loading, and at the same time, the dissolution rate is also relatively large improvement.

The invention relates to a device and a method for preparing a gel microsphere and a gel microsphere in which antitubercular agents can be injected. The device comprises: a porous shower nozzle, a collecting cup, a collecting tubule, a high pressure static generator, a constant current pump, a settling basin, an injection pump and an infiltration electrode. On the basis of a common static liquid drop generating device, the collecting tubule is arranged to form a liquid level flow regulating system, so that a liquid exchange passage exists between the collecting cup and the settling basin and can collect the low-density gel microspheres floating on the liquid level of the collecting cup and rapidly transfer the microspheres to the settling basin. Meanwhile, the built-in infiltration electrode type porous shower nozzle can enable the drug liquid droplet in drug-carrying sol solution to be fully charged, and form a uniform high electric field with the collecting tubule, thus enhancing the atomizing effect of the liquid column of the nozzle and enabling the drug-carrying sol solution to form monodispersity gel microspheres. The gel microsphere in which antitubercular agents can be injected contains rifapentine or rifabutin, made by the device and the method. The gel microsphere is high in yield, and large in drug-carrying capacity, and does not sink down or adhere after drying.